NeoGenomics Inc. Common Stock (NEO)

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in…

Sector

Health Care

Industry

Precision Instruments

Employees

2,500

Website

neogenomics.com/

Fundamentals

1-day range

$17.89$18.75

Market cap

$2.04B

P/E (trailing)

—

P/E (forward)

52.53

EPS (trailing)

$-0.40

Dividend yield

—

Beta

1.86

Avg. volume

2.84M

Forecasts

9 analyst ratings

NeoGenomics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• NEO

  NeoGenomics Inc. Common Stock

  $18.05

  ▼ 3.17%
  Market cap $2.04BP/E —
  $6.65$19.76
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.01BP/E —
  $7.48$18.57
• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $1.99BP/E —
  $13.18$34.29
• SGRY

  Surgery Partners Inc. Common Stock

  $13.69

  ▼ 1.72%
  Market cap $2.10BP/E —
  $11.41$23.44
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.10BP/E —
  $23$55.42
• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.13BP/E —
  $14.94$47.65

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors
  benzinga · 8/26/2026

• Greg D. Aunan · August 4, 2026 · Sale

  20.0K @ $16.07
• Starrett Carolyn S · June 23, 2026 · Grant

  14.1K
• Starrett Carolyn S · June 23, 2026 · Grant

  9.8K
• Lynn A. Tetrault · June 15, 2026 · Sale

  5.3K @ $11.1
• Lynn A. Tetrault · June 9, 2026 · Sale

  5.3K @ $11.29
• John P. Kenny · June 1, 2026 · Grant

  16.0K
• John P. Kenny · June 1, 2026 · Grant

  11.1K
• John P. Kenny · June 1, 2026 · Option Exercise

  5.9K
• Felicia Williams · June 1, 2026 · Grant

  16.0K
• Felicia Williams · June 1, 2026 · Grant

  11.1K
• Felicia Williams · June 1, 2026 · Option Exercise

  23.1K
• Lynn A. Tetrault · June 1, 2026 · Grant

  16.0K
• Lynn A. Tetrault · June 1, 2026 · Grant

  11.1K
• Lynn A. Tetrault · June 1, 2026 · Option Exercise

  23.1K
• David Brian Perez · June 1, 2026 · Grant

  16.0K

Institutional Ownership

March 31, 2026

Total shares held

125.75M

Total value held

$905.36M

Institutional holders

248